How does CELU's EPS compare to forecasts recently?

**Celularity's EPS is not currently available or comparable to forecasts.** Here's the analysis based on available data:

1. **No Data on EPS**: The latest report period for CELU is for Q3 2024, and no data on EPS or EPS surprise is available for this period or any other recent quarters.
2. **Focus on Net Sales**: Celularity has been reporting strong net sales trends, with significant growth in its advanced biomaterial products. For example, the company raised its full-year 2024 net sales guidance to $54 million to $60 million, up from $50 million to $56 million. This increase is driven by higher expected net sales through October, with October net sales reaching $8.3 million to $8.9 million, marking the highest single-month figure in Celularity's history.
3. **Strategic Initiatives**: Celularity's strategic initiatives, such as reducing SG&A expenses and implementing incentives aligned with shareholder interests, have contributed to its financial performance. The company's focus on manufacturing ramp-ups for advanced biomaterial products and acquisitions, like the Rebound product, have also boosted its revenue projections.

In conclusion, while specific EPS figures are not available, Celularity's net sales performance and strategic decisions indicate a positive financial trajectory.